Obesity / ACCG-2671 · Phase 1/2 Trial

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

ClinicalTrials.gov · September 11, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a first-in-human trial registration for ACCG-2671, a candidate obesity treatment, designed to evaluate safety, tolerability, pharmacokinetics, and food effects. No results are available in this registry record; the study is currently recruiting participants.

What was studied

Phase 1/2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Obesity; age from 25 Years; to 75 Years; accepts healthy volunteers. Intervention: Part 1 (SAD); Part 2 (Food-effect); ACCG-2671 Part 3 (MAD). Compared with: Placebo Part 1 (SAD) — Placebo Comparator; Placebo Part 3 (MAD) — Placebo Comparator. n = 164. 6 sites: United States.

Key findings

Safety

Results are not yet reported in this registry record; no safety, tolerability, or pharmacokinetic data are available

Who this may help

This record indicates an early developmental stage for ACCG-2671. Clinicians and researchers should await completion and publication of results before drawing conclusions about clinical utility or safety profile.

Plain-language summary

This is a first-in-human Phase 1/2 trial registration with no results posted; it describes planned safety, tolerability, and pharmacokinetic endpoints in an ongoing recruitment study.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Number of participants with one or more adverse events (AEs) as assessed by CTCAE v5.0 (assessed at Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, C…); Number of participants with one or more serious adverse advents (SAEs) as assessed by CTCAE v5.0 (assessed at Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, C…); Number of participants with one or more treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0 (assessed at Baseline to Day 21 (Part 2)); Change from baseline in systolic blood pressur…

DesignPhase 1/2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose

PopulationObesity; age from 25 Years; to 75 Years; accepts healthy volunteers

Sample size164

InterventionPart 1 (SAD); Part 2 (Food-effect); ACCG-2671 Part 3 (MAD)

ComparatorPlacebo Part 1 (SAD) — Placebo Comparator; Placebo Part 3 (MAD) — Placebo Comparator

Setting6 sites: United States

Reported figures

Quoted from the source exactly as published.

Planned enrollment164

Study phasePhase 1/2

Primary outcome measure (safety)Number of participants with one or more adverse events (AEs) as assessed by CTCAE v5.0

Primary outcome measure (pharmacokinetics)Change from baseline in systolic and diastolic blood pressure, heart rate, ECG parameters, hematologic, coagulation, and metabolic parameters

Clinical bottom line

Caveats

Results are not yet reported in this registry record; no safety, tolerability, or pharmacokinetic data are available
Specific eligibility criteria, inclusion/exclusion thresholds, and randomization ratio not detailed in source text
Study is actively recruiting; timeline to completion and results publication unknown
Food effect analysis endpoints noted in title but specific endpoints not explicitly detailed in primary outcome list

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

First-in-human, Phase 1/2, interventional, randomized to drug or placebo

Directness

moderate

Safety and tolerability endpoints measured directly; no clinical outcome data available

Consistency

insufficient

No results reported; cannot assess consistency with other evidence

Risk of bias

insufficient

Registry record only; blinding and allocation concealment not detailed in text

Sample adequacy

moderate

Estimated enrollment 164 participants; appropriate for Phase 1/2 dose escalation

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07815678). This is a study registration, not published results. Lead sponsor: Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 164 participants (ESTIMATED). Conditions: Obesity. Interventions: DRUG: ACCG-2671; DRUG: Placebo. Primary outcome measures: Number of participants with one or more adverse events (AEs) as assessed by CTCAE v5.0 , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Number of participants with one or more serious adverse advents (SAEs) as assessed by CTCAE v5.0 , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Number of participants with one or more treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0 , Baseline to Day 21 (Part 2); Change from baseline in systolic blood pressure , Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in diastolic blood pressure , Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in heart rate , Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in ECG ventricular heart rate , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3); Change from baseline in ECG PR interval , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3); Change from baseline ECG QRS duration , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3); Change from baseline in ECG QT Interval corrected using Fridericia's Formula (QTcF) , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3); Change from baseline in hemoglobin , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in hematocrit , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in thrombocyte count (platelet count) , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in white blood cell (WBC) count , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in prothrombin time , Baseline to day 17 (Part 1, Cohorts 1, 2, and 3); baseline to day 22 (Part 1, Cohorts 4 and 5); baseline to day 21 (Part 2); baseline to day 112 (Part 3); Change from baseline in international normalized ratio (INR) , Baseline to day 17 (Part 1, Cohorts 1, 2 and 3); baseline to day 22 (Part 1 Cohorts 4 and 5); baseline to day 21 (Part 2); baseline to day 112 (Part 3); Change from baseline in activated partial thromboplastin time (aPTT) , Baseline to day 17 (Part 1, Cohorts 1, 2 and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in fibrinogen activity , Baseline to Day 17 (Part 1, Cohorts 1, 2 and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in sodium , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in potassium , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in chloride , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in phosphate , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in calcium , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in glucose , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in amylase , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in lipase , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in magnesium , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3); Change from baseline in albumin , Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2);

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

ObesityAconcagua Bio, Inc. a wholly owned subsidiary of Structure TherapeuticsACCG-2671NCT07815678